Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018

Pooled efficacy and safety data from REVIVE Phase 3 trials presented

Data also published in peer-reviewed journal, International Journal of Antimicrobial Agents

NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that the pooled efficacy and safety data from its two Phase 3 trials (REVIVE-1 and REVIVE-2) in patients with acute bacterial skin and skin structure infections (ABSSSI) treated with its investigational drug candidate iclaprim were presented at the American Society of Microbiology (ASM) Microbe 2018 meeting in Atlanta, GA (An Analysis of Pooled …


Leave a Reply

Your email address will not be published.